{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:02:05Z","timestamp":1792800125962,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Idorsia Pharmaceuticals Ltd","award":["Idorsia Pharmaceuticals Ltd"],"award-info":[{"award-number":["Idorsia Pharmaceuticals Ltd"]}],"id":[{"id":"https:\/\/ror.org\/05j00sy30","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients presenting with an aneurysmal subarachnoid hemorrhage (aSAH), delayed cerebral ischemia (DCI) is a significant cause of morbidity and mortality. The REACT study is designed to assess the safety and efficacy of clazosentan in preventing clinical deterioration due to DCI in patients with aSAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>REACT is a prospective, multicenter, randomized phase 3 study that is planned to enroll 400 patients with documented aSAH from a ruptured cerebral aneurysm, randomized 1:1 to 15\u2009mg\/hour intravenous clazosentan vs. placebo, in approximately 100 sites and 15 countries. Eligible patients are required to present at hospital admission with CT evidence of significant subarachnoid blood, defined as a thick and diffuse clot that is more than 4\u2009mm in thickness and involves 3 or more basal cisterns. The primary efficacy endpoint is the occurrence of clinical deterioration due to DCI up to 14\u2009days post-study drug initiation. The main secondary endpoint is the occurrence of clinically relevant cerebral infarction at Day 16 post-study drug initiation. Other secondary endpoints include the modified Rankin Scale (mRS) and the Glasgow Outcome Scale-Extended (GOSE) score at Week 12 post-aSAH, dichotomized into poor and good outcome. Radiological results and clinical endpoints are centrally evaluated by independent committees, blinded to treatment allocation. Exploratory efficacy endpoints comprise the assessment of cognition status at 12\u2009weeks and quality of life at 12 and 24\u2009weeks post aSAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In the REACT study, clazosentan is evaluated on top of standard of care to determine if it reduces the risk of clinical deterioration due to DCI after aSAH. The selection of patients with thick and diffuse clots is intended to assess the benefit\/risk profile of clazosentan in a population at high risk of vasospasm-related ischemic complications post-aSAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration (Additional file 1)<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT03585270). EU Clinical Trial Register (EudraCT Number: 2018\u2013000241-39).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-03002-8","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:07:32Z","timestamp":1671494852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-6876","authenticated-orcid":false,"given":"Nicolas","family":"Bruder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Higashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Santin-Janin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Fran\u00e7ois","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"3002_CR1","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/STR.0b013e3182587839","volume":"43","author":"ES Connolly Jr","year":"2012","unstructured":"Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2012;43:1711\u201337.","journal-title":"Stroke"},{"key":"3002_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S1474-4422(09)70126-7","volume":"8","author":"DJ Nieuwkamp","year":"2009","unstructured":"Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8:635\u201342.","journal-title":"Lancet Neurol"},{"key":"3002_CR3","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1212\/WNL.0b013e3181dd42b3","volume":"74","author":"CE Lovelock","year":"2010","unstructured":"Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology. 2010;74:1494\u2013501.","journal-title":"Neurology"},{"key":"3002_CR4","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1161\/STROKEAHA.110.581975","volume":"41","author":"T Al-Khindi","year":"2010","unstructured":"Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2010;41:e519\u201336.","journal-title":"Stroke"},{"key":"3002_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3171\/jns.1978.48.2.0173","volume":"48","author":"B Weir","year":"1978","unstructured":"Weir B, Grace M, Hansen J, Rothberg C. Time course of vasospasm in man. J Neurosurg. 1978;48:173\u20138.","journal-title":"J Neurosurg"},{"key":"3002_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0967-5868(94)90005-1","volume":"1","author":"NW Dorsch","year":"1994","unstructured":"Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage part I: incidence and effects. J Clin Neurosci. 1994;1:19\u201326.","journal-title":"J Clin Neurosci"},{"key":"3002_CR7","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1161\/STROKEAHA.108.544700","volume":"40","author":"JA Frontera","year":"2009","unstructured":"Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N, et al. Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke. 2009;40:1963\u20138.","journal-title":"Stroke"},{"key":"3002_CR8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1161\/STROKEAHA.110.597005","volume":"42","author":"RW Crowley","year":"2011","unstructured":"Crowley RW, Medel R, Dumont AS, Ilodigwe D, Kassell NF, Mayer SA, et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke. 2011;42:919\u201323.","journal-title":"Stroke"},{"key":"3002_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2013.246","volume":"10","author":"RL Macdonald","year":"2014","unstructured":"Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10:44\u201358.","journal-title":"Nat Rev Neurol"},{"key":"3002_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/01.STR.0000163090.59350.5a","volume":"36","author":"AA Rabinstein","year":"2005","unstructured":"Rabinstein AA, Weigand S, Atkinson JL, Wijdicks EF. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke. 2005;36:992\u20137.","journal-title":"Stroke"},{"key":"3002_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00234-009-0575-y","volume":"51","author":"JW Dankbaar","year":"2009","unstructured":"Dankbaar JW, Rijsdijk M, van der Schaaf IC, Velthuis BK, Wermer MJ, Rinkel GJ. Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology. 2009;51:813\u20139.","journal-title":"Neuroradiology"},{"key":"3002_CR12","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2021.12.FOCUS21473","volume":"52","author":"L Rigante","year":"2022","unstructured":"Rigante L, van Lieshout JH, Vergouwen MDI, van Griensven CHS, Vart P, van der Loo L, et al. Time trends in the risk of delayed cerebral ischemia after subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Neurosurg Focus. 2022;52:E2.","journal-title":"Neurosurg Focus"},{"key":"3002_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/B978-0-444-63600-3.00012-X","volume":"140","author":"N Etminan","year":"2017","unstructured":"Etminan N, Macdonald RL. Management of aneurysmal subarachnoid hemorrhage. Handb Clin Neurol. 2017;140:195\u2013228.","journal-title":"Handb Clin Neurol"},{"key":"3002_CR14","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1093\/neuros\/nyz340","volume":"86","author":"J Brami","year":"2020","unstructured":"Brami J, Chousterman B, Boulouis G, Dorze ML, Majlath M, Saint-Maurice JP, et al. Delayed cerebral infarction is systematically associated with a cerebral vasospasm of large intracranial arteries. Neurosurgery. 2020;86:e175\u201383.","journal-title":"Neurosurgery"},{"key":"3002_CR15","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1016\/j.wneu.2014.05.011","volume":"82","author":"MN Stienen","year":"2014","unstructured":"Stienen MN, Smoll NR, Weisshaupt R, Fandino J, Hildebrandt G, Studerus-Germann A, et al. Delayed cerebral ischemia predicts neurocognitive impairment following aneurysmal subarachnoid hemorrhage. World Neurosurg. 2014;82:e599\u2013605.","journal-title":"World Neurosurg"},{"key":"3002_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000346087","volume":"35","author":"T Steiner","year":"2013","unstructured":"Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, et al. European stroke organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35:93\u2013112.","journal-title":"Cerebrovasc Dis"},{"key":"3002_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM198303173081103","volume":"308","author":"GS Allen","year":"1983","unstructured":"Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, et al. Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308:619\u201324.","journal-title":"N Engl J Med"},{"key":"3002_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3171\/jns.1988.68.4.0505","volume":"68","author":"KC Petruk","year":"1988","unstructured":"Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68:505\u201317.","journal-title":"J Neurosurg"},{"key":"3002_CR19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmj.298.6674.636","volume":"298","author":"JD Pickard","year":"1989","unstructured":"Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298:636\u201342.","journal-title":"BMJ"},{"issue":"Suppl 2","key":"3002_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2176\/nmc.st2013-0149","volume":"54","author":"K Hayashi","year":"2014","unstructured":"Hayashi K, Hirao T, Sakai N, Nagata I, group J-Ns. Current status of endovascular treatment for vasospasm following subarachnoid hemorrhage: analysis of JR-NET2. Neurol Med Chir (Tokyo). 2014;54(Suppl 2):107\u201312.","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"3002_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2176\/nmc.33.739","volume":"33","author":"I Fuwa","year":"1993","unstructured":"Fuwa I, Mayberg M, Gadjusek C, Harada T, Luo Z. Enhanced secretion of endothelin by endothelial cells in response to hemoglobin. Neurol Med Chir (Tokyo). 1993;33:739\u201343.","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"3002_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1006\/bbrc.2000.4167","volume":"280","author":"G Lin","year":"2001","unstructured":"Lin G, Macdonald RL, Marton LS, Kowalczuk A, Solenski NJ, Weir BK. Hemoglobin increases endothelin-1 in endothelial cells by decreasing nitric oxide. Biochem Biophys Res Commun. 2001;280:824\u201330.","journal-title":"Biochem Biophys Res Commun"},{"key":"3002_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/0026-0495(90)90157-8","volume":"39","author":"M Kohno","year":"1990","unstructured":"Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, Kanayama Y, et al. Thrombin stimulates the production of immunoreactive endothelin-1 in cultured human umbilical vein endothelial cells. Metabolism. 1990;39:1003\u20135.","journal-title":"Metabolism"},{"key":"3002_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411\u20135.","journal-title":"Nature"},{"key":"3002_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3171\/jns.1995.82.1.0055","volume":"82","author":"V Seifert","year":"1995","unstructured":"Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg. 1995;82:55\u201362.","journal-title":"J Neurosurg"},{"key":"3002_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1124\/pr.115.011833","volume":"68","author":"AP Davenport","year":"2016","unstructured":"Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacol Rev. 2016;68:357\u2013418.","journal-title":"Pharmacol Rev"},{"key":"3002_CR27","first-page":"1110","volume":"283","author":"S Roux","year":"1997","unstructured":"Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997;283:1110\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"3002_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3171\/jns.2005.103.1.0009","volume":"103","author":"P Vajkoczy","year":"2005","unstructured":"Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. Clazosentan (AXV-034343), a selective endothelin a receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005;103:9\u201317.","journal-title":"J Neurosurg"},{"key":"3002_CR29","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/STROKEAHA.108.519942","volume":"39","author":"RL Macdonald","year":"2008","unstructured":"Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39:3015\u201321.","journal-title":"Stroke"},{"key":"3002_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000475824","volume":"44","author":"M Fujimura","year":"2017","unstructured":"Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T. Preventive effect of clazosentan against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean patients. Cerebrovasc Dis. 2017;44:59\u201367.","journal-title":"Cerebrovasc Dis"},{"key":"3002_CR31","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1016\/j.wneu.2019.04.222","volume":"128","author":"RT Higashida","year":"2019","unstructured":"Higashida RT, Bruder N, Gupta R, Guzman R, Hmissi A, Marr A, et al. Reversal of vasospasm with clazosentan after aneurysmal subarachnoid hemorrhage: a pilot study. World Neurosurg. 2019;128:e639\u2013e48.","journal-title":"World Neurosurg"},{"key":"3002_CR32","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(11)70108-9","volume":"10","author":"RL Macdonald","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10:618\u201325.","journal-title":"Lancet Neurol"},{"key":"3002_CR33","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","volume":"43","author":"RL Macdonald","year":"2012","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43:1463\u20139.","journal-title":"Stroke"},{"key":"3002_CR34","doi-asserted-by":"crossref","unstructured":"Endo H, Hagihara Y, Kimura N, Takizawa K, Niizuma K, Togo O, et al. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022;137:1\u201311.","DOI":"10.3171\/2022.2.JNS212914"},{"key":"3002_CR35","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1161\/STROKEAHA.119.025682","volume":"50","author":"SA Mayer","year":"2019","unstructured":"Mayer SA, Aldrich EF, Bruder N, Hmissi A, Macdonald RL, Viarasilpa T, et al. Thick and diffuse subarachnoid blood as a treatment effect modifier of Clazosentan after subarachnoid hemorrhage. Stroke. 2019;50:2738\u201344.","journal-title":"Stroke"},{"key":"3002_CR36","doi-asserted-by":"crossref","unstructured":"Aldrich EF, Higashida R, Hmissi A, Le EJ, Macdonald RL, Marr A, et al. Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2020;134:1\u20139.","DOI":"10.3171\/2020.3.JNS193400"},{"key":"3002_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12028-012-9792-z","volume":"18","author":"BN Jaja","year":"2013","unstructured":"Jaja BN, Cusimano MD, Etminan N, Hanggi D, Hasan D, Ilodigwe D, et al. Clinical prediction models for aneurysmal subarachnoid hemorrhage: a systematic review. Neurocrit Care. 2013;18:143\u201353.","journal-title":"Neurocrit Care"},{"key":"3002_CR38","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/01.STR.0000027437.22450.BD","volume":"33","author":"JT Wilson","year":"2002","unstructured":"Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin scale. Stroke. 2002;33:2243\u20136.","journal-title":"Stroke"},{"key":"3002_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/neu.1998.15.573","volume":"15","author":"JT Wilson","year":"1998","unstructured":"Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow outcome scale and the extended Glasgow outcome scale: guidelines for their use. J Neurotrauma. 1998;15:573\u201385.","journal-title":"J Neurotrauma"},{"key":"3002_CR40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1515\/revneuro-2016-0021","volume":"27","author":"ZZ Chong","year":"2016","unstructured":"Chong ZZ. S100B raises the alert in subarachnoid hemorrhage. Rev Neurosci. 2016;27:745\u201359.","journal-title":"Rev Neurosci"},{"key":"3002_CR41","first-page":"13","volume":"28","author":"G Teasdale","year":"1979","unstructured":"Teasdale G, Murray G, Parker L, Jennett B. Adding up the Glasgow coma score. Acta Neurochir Suppl (Wien). 1979;28:13\u20136.","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"3002_CR42","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","volume":"41","author":"MD Vergouwen","year":"2010","unstructured":"Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41:2391\u20135.","journal-title":"Stroke"},{"key":"3002_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/neurintsurg-2011-010248","volume":"4","author":"T Abruzzo","year":"2012","unstructured":"Abruzzo T, Moran C, Blackham KA, Eskey CJ, Lev R, Meyers P, et al. Invasive interventional management of post-hemorrhagic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurointerv Surg. 2012;4:169\u201377.","journal-title":"J Neurointerv Surg"},{"key":"3002_CR44","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/01.STR.20.7.864","volume":"20","author":"T Brott","year":"1989","unstructured":"Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864\u201370.","journal-title":"Stroke"},{"key":"3002_CR45","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/jnnp.51.11.1457","volume":"51","author":"GM Teasdale","year":"1988","unstructured":"Teasdale GM, Drake CG, Hunt W, Kassell N, Sano K, Pertuiset B, et al. A universal subarachnoid hemorrhage scale: report of a committee of the world federation of neurosurgical societies. J Neurol Neurosurg Psychiatry. 1988;51:1457.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3002_CR46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"3002_CR47","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3389\/fneur.2019.00734","volume":"10","author":"MN Stienen","year":"2019","unstructured":"Stienen MN, Geisseler O, Velz J, Maldaner N, Sebok M, Dannecker N, et al. Influence of the intensive care unit environment on the reliability of the Montreal cognitive assessment. Front Neurol. 2019;10:734.","journal-title":"Front Neurol"},{"key":"3002_CR48","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1161\/01.STR.30.7.1362","volume":"30","author":"LS Williams","year":"1999","unstructured":"Williams LS, Weinberger M, Harris LE, Clark DO, Biller J. Development of a stroke-specific quality of life scale. Stroke. 1999;30:1362\u20139.","journal-title":"Stroke"},{"key":"3002_CR49","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/jnnp.2009.184960","volume":"81","author":"H Boosman","year":"2010","unstructured":"Boosman H, Passier PE, Visser-Meily JM, Rinkel GJ, Post MW. Validation of the stroke specific quality of life scale in patients with aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2010;81:485\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3002_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/PROM.S96822","volume":"7","author":"D Morley","year":"2016","unstructured":"Morley D, Dummett S, Kelly L, Dawson J, Fitzpatrick R, Jenkinson C. Validation of the Oxford participation and activities questionnaire. Patient Relat Outcome Meas. 2016;7:73\u201380.","journal-title":"Patient Relat Outcome Meas"},{"key":"3002_CR51","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"3002_CR52","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.1016\/j.wneu.2018.07.196","volume":"119","author":"Y Shen","year":"2018","unstructured":"Shen Y, Dong Z, Pan P, Shi H, Song Y. Risk factors for mild cognitive impairment in patients with aneurysmal subarachnoid hemorrhage treated with endovascular coiling. World Neurosurg. 2018;119:e527\u2013e33.","journal-title":"World Neurosurg"},{"key":"3002_CR53","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1227\/01.NEU.0000359317.15269.20","volume":"65","author":"MV Springer","year":"2009","unstructured":"Springer MV, Schmidt JM, Wartenberg KE, Frontera JA, Badjatia N, Mayer SA. Predictors of global cognitive impairment 1 year after subarachnoid hemorrhage. Neurosurgery. 2009;65:1043\u201350.","journal-title":"Neurosurgery"},{"key":"3002_CR54","doi-asserted-by":"publisher","first-page":"e0247942","DOI":"10.1371\/journal.pone.0247942","volume":"16","author":"K Chalard","year":"2021","unstructured":"Chalard K, Szabo V, Pavillard F, Djanikian F, Dargazanli C, Molinari N, et al. Long-term outcome in patients with aneurysmal subarachnoid hemorrhage requiring mechanical ventilation. PLoS One. 2021;16:e0247942.","journal-title":"PLoS One"},{"key":"3002_CR55","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/jcbfm.2011.56","volume":"31","author":"MD Vergouwen","year":"2011","unstructured":"Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2011;31:1545\u201353.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3002_CR56","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1161\/STROKEAHA.109.547331","volume":"40","author":"KT Kreiter","year":"2009","unstructured":"Kreiter KT, Mayer SA, Howard G, Knappertz V, Ilodigwe D, Sloan MA, et al. Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage. Stroke. 2009;40:2362\u20137.","journal-title":"Stroke"},{"key":"3002_CR57","first-page":"14","volume-title":"Impact of infarct aetiology on lesion size and clinical outcome in high-risk patients for vasospasm with thick and diffuse aSAH (abstract)","author":"S Roux","year":"2021","unstructured":"Roux S, Kovats D, Mayer SA. Impact of infarct aetiology on lesion size and clinical outcome in high-risk patients for vasospasm with thick and diffuse aSAH (abstract). Paris: 11th EURONEURO Congress; 2021. p. 14\u20136. p. Poster no. 1016"},{"key":"3002_CR58","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/STROKEAHA.106.477976","volume":"38","author":"S Weidauer","year":"2007","unstructured":"Weidauer S, Lanfermann H, Raabe A, Zanella F, Seifert V, Beck J. Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke. 2007;38:1831\u20136.","journal-title":"Stroke"},{"key":"3002_CR59","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1042\/CS20160452","volume":"131","author":"JM Biesbroek","year":"2017","unstructured":"Biesbroek JM, Weaver NA, Biessels GJ. Lesion location and cognitive impact of cerebral small vessel disease. Clin Sci (Lond). 2017;131:715\u201328.","journal-title":"Clin Sci (Lond)"},{"key":"3002_CR60","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3171\/JNS.2008.109.12.1052","volume":"109","author":"JM Schmidt","year":"2008","unstructured":"Schmidt JM, Wartenberg KE, Fernandez A, Claassen J, Rincon F, Ostapkovich ND, et al. Frequency and clinical impact of asymptomatic cerebral infarction due to vasospasm after subarachnoid hemorrhage. J Neurosurg. 2008;109:1052\u20139.","journal-title":"J Neurosurg"},{"key":"3002_CR61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fneur.2019.00123","volume":"10","author":"K Zheng","year":"2019","unstructured":"Zheng K, Zhong M, Zhao B, Chen SY, Tan XX, Li ZQ, et al. Poor-grade aneurysmal subarachnoid hemorrhage: risk factors affecting clinical outcomes in intracranial aneurysm patients in a multi-center study. Front Neurol. 2019;10:123.","journal-title":"Front Neurol"},{"key":"3002_CR62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12028-019-00723-6","volume":"30","author":"JI Suarez","year":"2019","unstructured":"Suarez JI, Sheikh MK, Macdonald RL, Amin-Hanjani S, Brown RD Jr, de Oliveira Manoel AL, et al. Common data elements for unruptured intracranial aneurysms and subarachnoid hemorrhage clinical research: a National Institute for neurological disorders and stroke and National Library of medicine project. Neurocrit Care. 2019;30:4\u201319.","journal-title":"Neurocrit Care"},{"key":"3002_CR63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.wneu.2015.08.052","volume":"85","author":"T Inagawa","year":"2016","unstructured":"Inagawa T. Risk factors for cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a review of the literature. World Neurosurg. 2016;85:56\u201376.","journal-title":"World Neurosurg"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03002-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-03002-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03002-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T22:07:37Z","timestamp":1671833257000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-03002-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3002"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-03002-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"8 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is conducted in full compliance with the International Conference on Harmonization Good Clinical Practice Guideline, the principles of the Declaration of Helsinki, and the laws and regulations of the country in which it is performed. The REACT protocol and amendments have been approved by research ethics committees\/institutional review boards in each participating investigational site (last amendment dated February 18, 2022, Additional file\n                      \n                      ). It is the responsibility of the investigator to obtain written informed consent from all participants prior to enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NB, RH, EFA, and SAM have been consultants \/ scientific advisors for Idorsia Pharmaceuticals Ltd. and have received consulting fees.HSJ, AM, and SR are employees of Idorsia Pharmaceuticals Ltd., and CD is an external contractor. Idorsia is the owner and developer of clazosentan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"492"}}